You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健民集團(600976.SH):葉開泰國藥簽訂2份《技術委託開發合同》
格隆匯 12-18 15:42

格隆匯12月18日丨健民集團(600976.SH)公佈,公司全資子公司健民集團葉開泰國藥(隨州)有限公司(以下簡稱:葉開泰國藥)擬分別與南京恆道醫藥科技有限公司、北京阜康仁生物製藥科技有限公司簽訂《技術委託開發合同》,委託其進行藥品的技術開發。

JMEY001藥品研發項目受託方為南京恆道醫藥科技有限公司,技術委託開發服務費480萬元,資金來源於葉開泰國藥自有資金。項目經營範圍包括醫藥化工產品研發與技術轉讓;醫療器械研發、技術服務及技術諮詢;檢測技術服務等。研究內容包括JMEY001藥品1個規格處方工藝篩選以及生產工藝指導和交接,並完成藥品研究及申報資料準備等相關工作,使葉開泰國藥最終獲得該項目的藥品生產批件。

JMEY002藥品研發項目受託方為北京阜康仁生物製藥科技有限公司,技術委託開發服務費550萬,資金來源於葉開泰國藥自有資金。項目經營範圍包括技術開發;技術轉讓;技術諮詢;技術服務;貨物進出口;銷售醫療器械I類、化粧品;銷售食品。按照國家《藥品註冊管理辦法》及NMPA的要求,北京阜康仁生物製藥科技有限公司提供該合同項下的仿製藥申報所需試驗、技術資料的專項技術開發,達到與原研藥品的質量和療效一致,協助葉開泰國藥最終獲得藥品批准文號。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account